Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux helped a group of cancer patients thought to be immune to the treatment in a study that contradicts earlier assumptions of the way the drug works in those with a genetic mutation.
Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux helped a group of cancer patients thought to be immune to the treatment in a study that contradicts earlier assumptions of the way the drug works in those with a genetic mutation.
